GigaCloud Tech (NASDAQ:GCT) Stock, Quote.Headers.trade-ideas

GigaCloud Tech

GigaCloud Technology Inc end-to-end B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.

News

Asset Sales

Small Cap

Markets

Analyst Ratings

Tech

Trading Ideas

BYON

RVLV

GigaCloud Technology Inc. (NASDAQ: GCT) has been on a downward spiral lately, with significant selling pressure. The stock has dipped 36.6% against the 9% increase of the industry it belongs to and the 10.5% growth of the Zacks S&amp;P 500 composite.

GigaCloud Down 37% in 6 Months: Should You Buy the Dip?

Earnings

CMRE

GPRK

HRMY

After all major indexes ended the first half of the year in the green, more gains are anticipated in the second half. The resilient economy, robust job market, upward-trending sales and earnings estimates, and near-record household incomes provide strong support for continued market growth.

5 High Earnings Yield Value Stocks That You Shouldn&#39;t Ignore

New analyst coverage greatly benefits investors by providing comprehensive data on stocks for an informed investment decision. Analysts possess information crucial for investors, and their insights are highly valued. Without them, stocks may be misinterpreted and potentially mispriced.


2 Stocks in Focus As New Analysts Initiate Coverage

GigaCloud Technology Inc - Class A Ordinary Shares

GigaCloud Technology Inc

GlucoTrack Inc

GCT Semiconductor Holding, Inc. Common Stock

GCT Semiconductor Holding Inc

GCT Semiconductor Holding, Inc. Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

CTSH

mecwacare, Cognizant Embark On Multi-year Relationship To Launch Digital Transformation Program

This will result in Vistra being the sole owner of its Vistra Vision subsidiary, which includes its zero-carbon nuclear, energy storage, and solar generation assets, as well as its retail business.
The net present value of the purchase price as of&nbsp;Dec. 31, 2024, discounted at a&nbsp;6%&nbsp;interest rate, is&nbsp;$3.085 billion.
The agreement does not impact or change Vistra&#39;s capital allocation priorities. Vistra remains committed to its long-term net leverage target of less than 3x2. Vistra also continues to expect to execute at least&nbsp;$2.25 billion&nbsp;of share repurchases in 2024 and 2025 and at least&nbsp;$1 billion&nbsp;in 20263, as well as pay&nbsp;$300 million&nbsp;in aggregate common dividends in each year 2024-20263.
&nbsp;

Vistra Enters Deal With Nuveen Asset Management And Avenue Capital To Acquire Their Combined 15% Equity Interest In Vistra Vision LLC For Undiscounted Purchase Price Of $3.248B Cash, To Be Paid In Five Installments

BLMZ

BloomZ Gets Nasdaq Notification Letter That It Is Not In Compliance With Minimum Market Value Requirement

Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) shares moved higher Wednesday as markets witnessed the first interest rate cut from the <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">Federal Reserve in four years. </a>
The Details: Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner Core Scientific's stock has climbed more than 20% over the past five days, as investors anticipated an interest rate cut. 
The Federal Reserve announced a 50 basis points (bps) cut Wednesday, bringing the federal funds rate down to a range of 4.75%-5% and increasing the appeal of risk assets like stocks and cryptocurrencies. 
Core Scientific shares climbed throughout Wednesday's session and spiked to an intraday high of $12.48  just after the announcement from Fed Chairman Jerome Powell. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/24/09/40910569/nvidia-salesforce-announce-strategic-ai-collaboration-what-to-know">NVIDIA, Salesforce Announce Strategic AI Collaboration: What To Know</a>
Earlier this month, Core Scientific CEO Adam Sullivan shared plans with Bernstein analysts to <a href="https://www.benzinga.com/top-stories/24/09/40800336/core-scientific-aims-for-25-30-billion-valuation-with-ai-data-center-services-bernstein">significantly expand</a> the company's AI data center services, potentially boosting its valuation to a range of $25 billion to $30 billion.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Core Scientific shares are trading above the stock&#8217;s 50-day moving average of $10.05 and just under its 52-week high of $12.25.&nbsp;
CORZ Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Core Scientific shares ended Wednesday's session up 4.79% at $12.03.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40904271/whats-going-on-with-amazon-stock">What&#8217;s Going On With Amazon Stock?</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$BTC

Core Scientific, Inc. - Class A Common Stock

CORZ

What Happened With Bitcoin Miner Core Scientific's Stock Today?

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares are moving higher Wednesday. Here&#8217;s <a href="https://www.benzinga.com/news/24/09/40917539/while-apple-abandoned-its-car-project-after-pouring-1b-into-it-its-key-supplier-foxconn-is-now-colla">what you need to know.</a>
What To Know: In significant economic development, the Federal Reserve instituted a<a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down"> 50 basis points cut</a>, bringing the federal funds rate to 4.75%–5%. This unexpected move, marking the first rate reduction in more than four years, reflects the Fed&#8217;s greater confidence in managing inflation. 
The Fed also revised its economic growth forecast for 2024 down to 2%. Inflation projections for the same year were also lowered, while unemployment rates were revised upward through 2026.
Future Rate Path: The updated Dot Plot suggests another 50 basis points in cuts in 2024 and an additional 100 basis points by the end of 2025, highlighting a more aggressive easing approach compared to previous projections. This outlook signals a significant shift from the Fed's earlier stance and impacts projections for economic metrics over the next few years.
See Also:<a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down"> Powell Defends 0.5% Interest Rate Drop As &#8216;Right Thing For The Economy,&#8217; Doubles Down On Fed&#8217;s Cautious, Data-Driven Approach</a>
What Else: The company formerly abandoned its electric vehicle (EV) project after significant investments. In contrast, its key supplier Hon Hai Precision Industry Co Ltd &#8211; ADR, also known as Foxconn, (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNHPF#OTC">HNHPF</a>) is advancing in the EV market. Foxconn, collaborating with Sharp, recently unveiled the LDK+ electric vehicle prototype. Designed with a room-like interior, the LDK+ aims to serve as a personal space, highlighting the evolving role of vehicles in the autonomous driving era.
Foxconn demonstrated strategic acumen by focusing on modular EV platforms that allow for cost-efficient, unique model creation. The company has also approved a $246 million investment in Northern Vietnam for manufacturing EV parts, with operations expected to start in January 2025. This investment underscores Foxconn's commitment to enhancing its production capabilities and positioning itself as a notable player in the EV industry.
AAPL Price Action: Apple shares closed Wednesday up 1.80% at $220.69, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="548" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1-1024x548.png" alt="" class="wp-image-554734" style="width:482px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1-1024x548.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40925721/crowdstrike-launches-ai-security-posture-management-to-enhance-cloud-protection">CrowdStrike Launches AI Security Posture Management To Enhance Cloud Protection</a></li>
</ul>
Photo: Courtesy Apple Inc.

After-Hours Center

AAPL

HNHPF

Apple Shares Are Trading Higher Today: What You Need To Know

INCY

SNDX

Incyte, Syndax Report Publication Of Data From Pivotal AGAVE-201 Trial Of Niktimvo; Trial Met The Primary Endpoint Across All Cohorts

Northrop Grumman Says B-21 Raider Program Is Making Progress As The Team Executes Flight Test Campaign And Scales Into Production

Guidance

SANG

Sangoma Expects FY25 Revenue Of $250M - $260M; Q1 Revenue Of $61M - $62M

Cryptocurrency markets are trading relatively flat after the <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">Federal Reserve announced a 50-basis-point interest rate cut</a>, making risk assets more attractive.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$60,376.37</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,322.72</td>
<td>-1.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$130.3</td>
<td>-1.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.101</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001334</td>
<td>-0.04%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows an 8% decline in large transaction volume and a 4% increase in daily active addresses. Transactions greater than $100,000 increased from 7,579 to 8,280 in single day. Exchanges netflows narrowed by 238%.</li>
<li>Coinglass data shows 56,823 traders were liquidated in the past 24 hours for $124 million.</li>
<li>HODL15Capital <a href="https://x.com/HODL15Capital/status/1836412436250865968">noted</a> that U.S. Bitcoin ETFs continue to buy more than 100% of newly mined BTC. The ETFs bought 2,921 Bitcoin yesterday vs. 450 mined.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40922909/revolut-plans-to-launch-stablecoin-crypto-is-part-of-our-belief-in-banking-without-borders">Revolut Plans To Launch Stablecoin: &#8216;Crypto Is Part Of Our Belief In Banking Without Borders&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40913998/jamie-dimon-says-jpmorgan-is-likely-one-of-the-bigger-users-of-blockchain-technology-but-c">Jamie Dimon Says JPMorgan Is Likely &#8216;One Of The Bigger Users&#8217; Of Blockchain Technology, But Calls Cryptocurrencies A &#8216;Pet Rock&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919168/ethereum-co-founder-says-donald-trump-is-certainly-the-favorite-over-kamala-harris-for-cry">Ethereum Co-Founder Says Donald Trump Is &#8216;Certainly The Favorite&#8217; Over Kamala Harris For Crypto</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40924865/hamster-kombat-to-launch-game-development-ecosystem-aiming-to-onboard-next-billion-into-we">Hamster Kombat To Launch Game Development Ecosystem, Aiming To Onboard &#8216;Next Billion&#8217; Into Web3</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40913080/shiba-inu-team-says-launching-k9-finance-liquid-staking-on-shibarium-tomorrow-are-shib-bur">MicroStrategy Raises $875M In Convertible Notes, Plans Further Bitcoin Purchases</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40913080/shiba-inu-team-says-launching-k9-finance-liquid-staking-on-shibarium-tomorrow-are-shib-bur">Shiba Inu Team Says Launching K9 Finance Liquid Staking On Shibarium Tomorrow: Are SHIB Burns Set To Accelerate From Here On Now?</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Nervos Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ckb/usd">CKB</a>)</td>
<td>$0.01754&nbsp;&nbsp;</td>
<td>+10%</td>
</tr>
<tr>
<td>Fantom (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ftm/usd">FTM</a>)</td>
<td>$0.6171</td>
<td>+8.2%</td>
</tr>
<tr>
<td>BinaryX (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BNX</a>)</td>
<td>$1.56</td>
<td>+7.8%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto chart analyst Ali Martinez predicts that today's close above $61,500 "could signal the resumption of the bull market! Uptober."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> attempts to break through an important trend line. Closing today above $61,500 could signal the resumption of the bull market! <a href="https://twitter.com/hashtag/Uptober?src=hash&amp;ref_src=twsrc%5Etfw">#Uptober</a> &#x1f440; <a href="https://t.co/CU2a38Jsdh">pic.twitter.com/CU2a38Jsdh</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1836475047625560515?ref_src=twsrc%5Etfw">September 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">Another trader Satoshi Flipper calls this FOMC decision bullish for risk assets like Bitcoin and crypto assets. He added that 50 basis points is more bullish than 25 basis points. He <a href="https://x.com/SatoshiFlipper/status/1836468861174198325">concluded</a>, "cost of borrowing just got even cheaper, hence companies will make more and have more capital available for investing in BTC/risk assets." &nbsp; Another crypto trader, More Crypto Online, predicts that a "break above yesterday&#8217;s high would open the door to $67,000." He <a href="https://x.com/Morecryptoonl/status/1836473875187560632">called</a> the price action a good reaction to the support zone and bulls need to hold above the trend channel for further upside momentum. &nbsp; Crypto Bully provided both long and short trade plans for Bitcoin. Suggesting how to trade, "Look for a retest with good volume to long towards $61,500 for a continuation long."</figcaption></figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Update: Both Long and short trade plans &#8211; Powell says that 50bps rate cuts should not be seen as the norm going forward, also says labor market bears close watching &#8211; BTC just following equities the entire day today. Open Interest up 4% since FOMC number release &#8211; Both… <a href="https://t.co/nchUhNYRWD">pic.twitter.com/nchUhNYRWD</a>
&mdash; Crypto Bully &#x1f525; (@BullyDCrypto) <a href="https://twitter.com/BullyDCrypto/status/1836479545697816826?ref_src=twsrc%5Etfw">September 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40908610/whale-games-bitcoin-trader-takes-11-6m-profit-but-guess-how-much-more-theyre-sitting-on">Whale Games: Bitcoin Trader Takes $11.6M Profit But Guess How Much More They&#8217;re Sitting On</a></li>
</ul>

$BNX

$CKB

$DOGE

$ETH

$FTM

$SHIB

$SOL

Bitcoin, Ethereum, Dogecoin Cheer Fed's Decision, Erase Early Losses: Close Above $61.5K Is 'Resumption Of Bull Market,' Says Trader

Sangoma Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANG#NASDAQ">SANG</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. The company reported quarterly sales of $60.93 million which missed the analyst consensus estimate of $61.03 million by 0.16 percent. This is a 4.31 percent decrease over sales of $63.68 million the same period last year.

Earnings Misses

Sangoma Technologies Q4 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $60.93M Miss $61.03M Estimate

iLearningEngines and GenLab Ventures&#39; alliance will initially focus on accelerating digital transformation for global multinationals in Japan, India, the Middle East, and the Americas by applying Generative AI to assist Chief Digital Officers and Chief Learning Officers.&nbsp;

AILE

iLearningEngines Enters Strategic Alliance With GenLab Venture Studio

FANH

Fanhua Reports H1 Earnings Per ADS Of $0.01, Total Net Revenues Of $154.55M

Management

AMKR

Amkor Says James Kim Will Be Stepping Down As Executive Chairman And Retiring From Company Effective October 31, 2024; Susan Kim, Executive Vice Chairman, To Become Chairman Of Board At That Time

ALGS

Aligos Therapeutics Plans To Share Topline Results From Phase 2a HERALD Study Of ALG-055009 In Metabolic-dysfunction Associated Steatohepatitis Subjects

During the last three months, 4 analysts shared their evaluations of TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.0, a high estimate of $49.00, and a low estimate of $20.00. Observing a 4.83% increase, the current average has risen from the previous average price target of $36.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1726693292_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of TG Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TG Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TG Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of TG Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of TG Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TGTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TG Therapeutics analyst ratings.</a>
<h2>All You Need to Know About TG Therapeutics</h2>
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
<h3>TG Therapeutics's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, TG Therapeutics showcased positive performance, achieving a revenue growth rate of 357.05% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: TG Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of 9.36%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): TG Therapeutics's ROE excels beyond industry benchmarks, reaching 4.07%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): TG Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.78%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.63, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TGTX

Evaluating TG Therapeutics: Insights From 4 Financial Analysts

In the preceding three months, 6 analysts have released ratings for Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.17, a high estimate of $78.00, and a low estimate of $35.00. This upward trend is apparent, with the current average reflecting a 34.4% increase from the previous average price target of $37.33.
<img src="https://www.benzinga.com/files/images/story/2024/1726693276_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Corcept Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corcept Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Corcept Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Corcept Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CORT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corcept Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Corcept Therapeutics</h2>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
<h3>Unraveling the Financial Story of Corcept Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Corcept Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 39.15%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Corcept Therapeutics's net margin excels beyond industry benchmarks, reaching 21.44%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corcept Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 6.14%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Corcept Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.13%, the company showcases efficient use of assets and strong financial health.
Debt Management: Corcept Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CORT

Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics

21 analysts have expressed a variety of opinions on PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $78.62, a high estimate of $95.00, and a low estimate of $69.00. This current average reflects an increase of 3.65% from the previous average price target of $75.85. 
<img src="https://www.benzinga.com/files/images/story/2024/1726693235_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of PayPal Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kazuya Nishimura</td>
<td>Daiwa Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$72.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Anthony Butler</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$83.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Harshita Rawat</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Gus Gala</td>
<td>Monness, Crespi, Hardt</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Anthony Butler</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>David Togut</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$69.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PayPal Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of PayPal Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of PayPal Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into PayPal Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PYPL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PayPal Holdings analyst ratings.</a>
<h2>Get to Know PayPal Holdings Better</h2>
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 426 million active accounts at the end of 2023. The company also owns Venmo, a person-to-person payment platform.
<h3>PayPal Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: PayPal Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.21%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 14.31%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): PayPal Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.46%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): PayPal Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.35%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.47, PayPal Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PYPL

Key Takeaways From PayPal Holdings Analyst Ratings

Ratings for Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $91.8, a high estimate of $104.00, and a low estimate of $80.00. Observing a downward trend, the current average is 3.2% lower than the prior average price target of $94.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1726693214_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Wyndham Hotels &amp; Resorts by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$104.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$91.50</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Announces</td>
<td>Neutral</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Wyndham Hotels &amp; Resorts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Wyndham Hotels &amp; Resorts compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Wyndham Hotels &amp; Resorts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Wyndham Hotels &amp; Resorts's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Wyndham Hotels &amp; Resorts analyst ratings.</a>
<h2>Get to Know Wyndham Hotels &amp; Resorts Better</h2>
As of Dec. 31, 2023, Wyndham Hotels &amp; Resorts operates 872,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 19% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 57% of total rooms.
<h3>A Deep Dive into Wyndham Hotels &amp; Resorts's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Wyndham Hotels &amp; Resorts displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 1.38%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Wyndham Hotels &amp; Resorts's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.43%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Wyndham Hotels &amp; Resorts's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.26% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Wyndham Hotels &amp; Resorts's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.09%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 3.9, Wyndham Hotels &amp; Resorts faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 5 Analyst Recommendations For Wyndham Hotels & Resorts

The dividend will be payable on October 31, 2024, to stockholders of record at the close of business on October 23, 2024.

Dividends

Argan Boosts Quarterly Cash Dividend By 25% From $0.30 To $0.375 Per Share

Steelcase Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) shares are falling after the company reported its second-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/09/g40927742/steelcase-reports-second-quarter-fiscal-2025-results">details from the report. </a>
The Details: Steelcase reported quarterly earnings of 39 cents per share, which beat the analyst consensus estimate of 37 cents. Quarterly revenue of $855.8 million missed the analyst consensus estimate of $864.1 million by 0.96%. 
The company saw growth in the Americas, driven by higher volume from large corporate, education and government customers, while International business declined, primarily driven by continued weakness in China.
&#8220;Our business continued to improve this quarter as our adjusted earnings grew 26% and we drove 3% order growth in the Americas,&#8221; said Sara Armbruster, president and CEO. &#8220;Our education business had especially strong results this quarter, which reflected the benefits of our strategy to diversify the customers and markets we serve.
Read Next: <a href="https://www.benzinga.com/news/large-cap/24/09/40910569/nvidia-salesforce-announce-strategic-ai-collaboration-what-to-know">NVIDIA, Salesforce Announce Strategic AI Collaboration: What To Know</a>
Outlook: Steelcase sees third-quarter revenue in a range of $785 million to $810 million and adjusted earnings of between 21 cents and 25 cents per share. 
SCS Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Steelcase shares are down 10.21% after-hours at $12.67 at the time of publication Wednesday. 
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40904271/whats-going-on-with-amazon-stock">What&#8217;s Going On With Amazon Stock?</a></li>
</ul>
Photo: Oleg Gamulinskii from Pixabay

Steelcase Stock Falls After Q2 Revenue Miss: Details

Amid signs of easing inflation and solid economic activity, savvy investors are eyeing under-the-radar opportunities with massive upside potential. Discover why MGM Resorts (MGM), UiPath (PATH), and GigaCloud (GCT) could be smart picks as these stealthy stocks capitalize on emerging market trends. Keep reading... In the fast-paced investing world, the most promising opportunities often lie beneath the radar. While headlines tend to spotlight the high-flying tech giants or the latest market sensations, several stealthy stocks quietly accumulate value, positioning themselves for significant gains.
These hidden gems are poised to deliver substantial upside potential as they continue to execute their growth strategies and capitalize on emerging market trends. So, it could be wise to invest in stealthy stocks MGM Resorts International (<a href="https://stocknews.com/stock/MGM/">MGM</a>), UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>), and GigaCloud Technology Inc. (<a href="https://stocknews.com/stock/GCT/">GCT</a>) with massive upside potential.
The <a href="https://www.cnbc.com/2024/08/02/job-growth-totals-114000-in-july-much-less-than-expected-as-unemployment-rate-rises-to-4point3percent.html">U.S. job growth slowed more than expected</a> in July, and the unemployment rate surged to 4.3%, fueling fears of a broader economic slowdown. Nonfarm payrolls rose by 114,000 for the month, down from 179,000 in June and below the Dow Jones estimate of 185,000. However, annual inflation dipped below 3% in July for the first time since 2021.
Easing inflation is a relief to investors anticipating a Federal Reserve interest rate cut next month, as a sense of unease has gripped Wall Street following signs of a cooling labor market. Moreover, <a href="https://www.cnbc.com/2024/07/25/us-gdp-q2-2024.html">economic activity in the U.S.</a> was stronger than expected in the second quarter, driven by a solid consumer, government spending, and a sizeable inventory build.
The personal consumption expenditures (PCE) price index increased by 2.6% for the second quarter, down from a 1.4% rise in the first quarter. Economists surveyed by Dow Jones estimated growth of 2.1%.
According to Treasury Secretary Janet Yellen, the GDP report is "affirming the path we're on to steady growth and declining inflation."
Amid this macroeconomic backdrop, explore stocks MGM, PATH, and GCT currently flying under the radar. These companies, each operating in distinct sectors, have shown strong fundamentals, innovative approaches, and strategic advantages that set them apart from their peers.
Let's discuss the fundamentals of the featured stocks in detail:
MGM Resorts International (<a href="https://stocknews.com/stock/MGM/">MGM</a>)
MGM owns and operates casinos, hotels, and entertainment resorts internationally. The company operates through three segments: Las Vegas Strip Resorts; Regional Operations; and MGM China. Its customers include premium gaming customers, leisure and wholesale travel customers, business travelers, and group customers, such as conventions and trade associations.
On August 15, MGM and Grupo Globo, Latin America's leading media group, announced a new venture to seek a sports betting and iGaming license in Brazil. If the license is approved later this year, the venture will launch in Brazil in early 2025 under the BetMGM brand, offering a responsible and top-tier betting platform to one of the world's fastest-growing regulated markets.
The new BetMGM-branded venture in strategic alliance with Grupo Globo will allow MGM to quickly enter the market with the scale and expertise required to establish an early foothold as a prominent operator and provider of the best experience to customers across Brazil.
For the second quarter that ended June 30, 2024, MGM's casino revenues were $2.21 billion, up 13.4% year-over-year. Its total revenues increased 9.8% year-over-year to $4.33 billion. Its operating income rose 14.6% from the prior year's quarter to $425.66 million. Furthermore, its adjusted EPS grew 45.8% from the year-ago value to $0.86.
Analysts expect MGM's revenue and EPS for the fiscal year (ending December 2024) to increase 7.4% and 3.9% year-over-year to $17.36 billion and $2.77, respectively. Moreover, the company surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past three months, the stock has plunged 4.7% to close the last trading session at $39.40. However, MGM's 12-month price forecast of $55.67 indicates an <a href="https://www.tipranks.com/stocks/mgm/forecast">upside potential of 41.3%</a>.
MGM's sound fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
MGM has a B grade for Value. It is ranked #14 among 25 stocks within the B-rated <a href="https://stocknews.com/category/entertainment-casinos-gambling/">Entertainment - Casinos/Gambling</a> industry.
To see the additional ratings of MGM for Quality, Growth, Momentum, Stability, and Sentiment, <a href="https://stocknews.com/stock/MGM/">click here</a>.
UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>)
PATH provides an end-to-end automation platform that offers a diverse range of robotic process automation (RPA) solutions, primarily in the U.S., Romania, the United Kingdom, and the Netherlands.
On July 2, UiPath introduced new features in its platform which infuse GenAI deeply into the UiPath Business Automation Platform&#x2122; to help businesses achieve better outcomes with AI and automation. The company fulfills the promise of AI-powered productivity with the launch of UiPath Autopilot&#x2122; for developers and testers. These innovations should bode well for the company.
In May, PATH announced an integration between the UiPath Business Automation Platform and Microsoft Copilot for Microsoft 365. This collaboration will allow joint customers to automate more knowledge work and improve end-user experiences with UiPath. Microsoft Azure remains a preferred cloud platform for UiPath, including UiPath Automation Cloud&#x2122;.
During the first quarter that ended April 30, 2024, PATH's total revenue increased 15.7% year-over-year to $335.12 million. Its non-GAAP <a href="https://www.investopedia.com/terms/g/grossprofit.asp">gross profit</a> rose 13.7% from the year-ago value to $288.21 million. Its non-GAAP net income and net income per share were $73.22 million and $0.13, up 14.8% and 18.2% from the prior-year quarter, respectively.
Street expects PATH's revenue for the second quarter (ended July 2024) to increase 5.7% year-over-year to $303.67 million. The consensus revenue estimate of $1.41 billion for the fiscal year ending January 2025 indicates an improvement of 7.7% year-over-year. Moreover, the company topped consensus revenue and EPS estimates in all four trailing quarters.
PATH's stock has gained 2.5% over the past five days and marginally over the past month to close the last trading session at $12.09. Further, the stock's 12-month price forecast of $15.62 indicates an <a href="https://www.tipranks.com/stocks/path/forecast">upside potential of 29.2%</a>.
PATH's POWR Ratings reflect its promising prospects. The stock has a B grade for Quality. It is ranked #12 out of 18 stocks in the A-rated <a href="https://stocknews.com/category/software-saas/">Software – SAAS</a> industry.
<a href="https://stocknews.com/stock/PATH/">Click here</a> to see the additional POWR Ratings for PATH (Sentiment, Growth, Value, Momentum, and Stability).
GigaCloud Technology Inc. (<a href="https://stocknews.com/stock/GCT/">GCT</a>)
GCT offers end-to-end B2B e-commerce solutions for large parcel merchandise. It provides GigaCloud Marketplace, which integrates product discovery, payments, and logistics tools into one platform. Its marketplace connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions across furniture, home appliances, and more.
On April 30, GCT announced that its global fulfillment network exceeded 10 million square feet of total space after the signing of a new lease in Ontario, California. This expansion bolsters GigaCloud's capacity to support the continued growth of its B2B marketplace and deliver enhanced fulfillment services to its B2B marketplace participants.
On April 4, GCT launched its industry-first service, "Branding-as-a-Service" or "BaaS," which is designed to improve the competitiveness of furniture suppliers, where the GigaCloud BaaS Program selects and allows sellers in the B2B GigaCloud Marketplace to sell products under one of the leading American furniture brands, Christopher Knight Home.
GCT's total revenues increased 103.1% year-over-year to $310.90 million in the second quarter that ended June 30, 2024. The company's gross profit grew 89.1% from the year-ago value to $76.40 million. Its adjusted EBITDA came in at $42.70 million, up 71.5% from the previous year's quarter.
In addition, the company's adjusted EPS rose 68.9% year-over-year to $1.03. Its cash, cash equivalents, restricted cash, and investments were $209.70 million as of June 30, 2024, compared to $184.20 million as of December 31, 2023.
Analysts expect GCT's revenue and EPS for the third quarter (ending September 2024) to increase 58.3% and 21.5% year-over-year to $282 million and $0.72, respectively. Further, the company surpassed consensus revenue estimates in each of the trailing four quarters.
Shares of GCT have surged 20.9% year-to-date and 75.7% over the past year to close the last trading session at $22.12. Additionally, the stock's 12-month price forecast of $59.50 indicates an <a href="https://www.tipranks.com/stocks/gct/forecast">upside potential of 169%</a>.
GCT's solid outlook is reflected in its POWR Ratings. The stock has a B grade for Momentum and Value.
Within the <a href="https://stocknews.com/category/technology-services/">Technology – Services</a> industry, GCT is ranked #26 out of 75 stocks. <a href="https://stocknews.com/stock/GCT/">Click here</a> to access additional ratings of GCT for Sentiment, Quality, Growth, and Stability.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
MGM shares rose $0.10 (+0.25%) in premarket trading Wednesday. Year-to-date, MGM has declined -11.82%, versus a 18.29% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Mangeet Kaur Bouns</h2> <img src='https:/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg' style="float:left; padding:5px;width:125px;">Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.<a href="https://stocknews.com/authors/?author=mangeet-kaurbouns">More...</a>The post <a href=https://stocknews.com/news/mgm-path-gct-3-stealthy-stocks-with-massive-upside-potential/>3 Stealthy Stocks With Massive Upside Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Stealthy Stocks With Massive Upside Potential

GigaCloud: Bullish Support Missing - High Growth Goes Unrewarded For Now (Downgrade)

GigaCloud Technology: Why I'm Blowing Away The Short Storm

GigaCloud Technology approves $46M share buyback program

Lake Street analyst Ryan Meyers maintained a Buy rating on GigaCloud Technology, Inc. Class A (GCT – Research Report) today and set a price target ...

GigaCloud Technology, Inc. Class A (GCT) Receives a Buy from Lake Street

6%-Yielding Hooker Furnishings: Stocks Bottom On Bad News

GigaCloud Technology: Business Model's Efficiency Is Questionable

Warning: GCT is at high risk of performing badly

GigaCloud Technology: The Bloodbath Should Stop Eventually

HOFT

PATH

Grizzly Research Releases Coverage Report on GigaCloud (NASDAQ:GCT)

Legal

Press Releases

Investigation Into GigaCloud Technology Inc. (GCT) Announced by Holzer & Holzer, LLC

GigaCloud Technology Inc Responds to Short-Seller Report

GigaCloud Technology Inc Wins Stevie® Award for Achievement in Growth

GigaCloud Technology Inc's Founder, Chairman, and CEO Larry Wu Named Entrepreneur Of The Year® 2024 Greater Los Angeles Award Winner

GigaCloud Technology Inc Joins Russell 2000 Index

GigaCloud Technology Inc to Announce Second Quarter and First Half 2024 Financial Results on August 6, 2024

GigaCloud Technology Inc Announces Second Quarter and Six Months Ended June 30, 2024 Financial Results

GigaCloud Technology Inc Announces CFO Transition

GigaCloud Technology Inc Announces $46 Million Share Repurchase Program

Alliance Entertainment Holding Corporation - common stock

Alliance Entertainment

A-Mark Precious Metals, Inc. - Common Stock

A-Mark Precious Metals

Cheetah Net Supply Chain Service Inc. - Class A Common Stock

Cheetah Net Supply Chain

Amcon Distributing

Educational Development Corporation - Common Stock

Educational Development

Greenlane Holdings, Inc. - Class A Common Stock

Greenlane Hldgs

Genuine Parts

J-Long Group

Kaival Brands Innovations Group, Inc. - Common Stock

Kaival Brands Innovations

Pool

Raytech Holding Limited - ordinary shares

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

GigaCloud Tech

GigaCloud Tech (GCT) Forecast

GigaCloud Tech (NASDAQ:GCT) Stock, Quote.Headers.trade-ideas